Literature DB >> 3501870

Serum alpha-1-protease inhibitor activity and pulmonary function in young insulin-dependent diabetic subjects.

M Sandler1, R I Stewart, B M Gemperli, C Hanekom, S H Kühn.   

Abstract

Abnormalities of lung function have previously been described in patients with impaired alpha 1-protease inhibitor (alpha 1-PI) function and more recently in insulin-dependent diabetic subjects. This study was undertaken to test the hypothesis that impaired alpha 1-PI activity may be implicated in the pathogenesis of lung function abnormalities in young insulin-dependent diabetic patients. Twelve young (16.23 +/- 4.51 years), non-smoking insulin-dependent diabetic subjects and 12 reference subjects were evaluated in respect of lung mechanics, absolute serum alpha 1-PI levels and the functional ability of alpha 1-PI to inhibit elastase. Results of the ventilatory mechanics showed that the mean value for the volume-independent index of lung elasticity Kst(L) was significantly greater in the diabetic group (0.149 +/- 0.05 vs. 0.116 +/- 0.03; p less than 0.05). The absolute serum alpha 1-PI levels in the insulin-dependent diabetic subjects was significantly lower than in reference subjects (1.74 +/- 0.11 vs. 2.06 +/- 0.09 g/l; p less than 0.05). While the specific alpha 1-PI activity of the diabetic sera showed no significant difference from that of the reference sera, the total alpha 1-PI inhibitory activity in the diabetic sera was significantly lower than reference values (201.9 +/- 9.7 vs. 246.9 +/- 13.5 U/L; p less than 0.02). Although these findings indicate impairment of both ventilatory mechanics and alpha 1-PI activity in the insulin-dependent diabetic subjects, the pathogenesis of these findings and their functional implications are at present unknown.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3501870     DOI: 10.1159/000195337

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  3 in total

Review 1.  Mechanistic evidence in support of alpha1-antitrypsin as a therapeutic approach for type 1 diabetes.

Authors:  Gabriella Fleixo-Lima; Hilla Ventura; Michal Medini; Liliana Bar; Pnina Strauss; Eli C Lewis
Journal:  J Diabetes Sci Technol       Date:  2014-08-25

2.  Diffusing capacity for carbon monoxide in children with type 1 diabetes.

Authors:  M P Villa; M Montesano; M Barreto; J Pagani; M Stegagno; G Multari; R Ronchetti
Journal:  Diabetologia       Date:  2004-11-24       Impact factor: 10.122

3.  Identification and purification from the plasma of Type 1 diabetic subjects of a proteolytically active Grp94Evidence that Grp94 is entirely responsible for plasma proteolytic activity.

Authors:  A Pagetta; A Folda; A M Brunati; P Finotti
Journal:  Diabetologia       Date:  2003-06-25       Impact factor: 10.122

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.